Agency
Triad Medical Group PA
Triad Medical Group PA was paid $3.24M by Medicaid between Jan 2018 and Oct 2023, across 33 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 41% of everything it billed.
33Billing provider infoTRIAD MEDICAL GROUP PA
GREENSBORO, NC 27406
GREENSBORO, NC 27406
33aNPI1194267336assigned 11/04/2016
33bProvider typeCommunity/Behavioral Health Agency
28Total paid$3.24M
24GClaims60,112
24DCodes billed33
24AFirst – last monthJan 2018 – Oct 2023
Compared with peers
Next to other Community/Behavioral Health Agency providers in North Carolina
Rank by total paid#240 of 856
Median peer was paid$908K
This provider vs. median3.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 22,868 | $1.84M | |
| 2019 | 10,405 | $777K | |
| 2020 | 4,079 | $298K | |
| 2021 | 7,332 | $200K | |
| 2022 | 8,912 | $91K | |
| 2023 | 6,516 | $32K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 41% | 15,261 | 12,134 | $1.34M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 8.8% | 5,537 | 4,345 | $285K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 8.3% | 4,307 | 3,172 | $270K |
| 90837 | Psychotherapy session, about an hourPsychotherapy, 53 minutes with patient | 8.1% | 2,465 | 1,260 | $263K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 7.7% | 1,548 | 746 | $250K |
| T1023 | Screening to determine the appropriateness of consideration of an individual for participation in a specified program, project or treatment protocol, per encounter | 5.5% | 797 | 692 | $180K |
| 99199 | Unlisted special service, procedure or report | 3.4% | 19,088 | 11,716 | $109K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 3.0% | 1,434 | 1,334 | $98K |
| H0015 | Alcohol and/or drug services; intensive outpatient (treatment program that operates at least 3 hours/day and at least 3 days/week and is based on an individualized treatment plan), including assessment, counseling; crisis intervention, and activity therapies or education | 2.3% | 572 | 81 | $75K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 2.1% | 745 | 687 | $68K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 2.0% | 520 | 460 | $65K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 1.8% | 418 | 392 | $60K |
21 more codes
| 99215 | Doctor's office visit, returning patient (complex) | 1.3% | 380 | $42K |
| H2022 | Community-based wrap-around services, per diem | 1.3% | 179 | $42K |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 275 | $17K |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 640 | $16K |
| Q3014 | Telehealth originating site facility fee | <1% | 814 | $15K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,382 | $14K |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 257 | $9K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 362 | $6K |
| 93000 | <1% | 383 | $5K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,606 | $3K |
| 99490 | Ccm add 20min | <1% | 509 | $3K |
| 90847 | Family psychotherapy with the patient present, 50 minutes | <1% | 24 | $2K |
| 96127 | <1% | 283 | $1K | |
| 99487 | Ccm add 20min | <1% | 71 | $646.02 |
| 90688 | <1% | 58 | $310.65 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 30 | $221.54 |
| 99406 | <1% | 41 | $187.74 | |
| 90836 | <1% | 51 | $113.44 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 16 | $108.34 |
| 81001 | <1% | 16 | $36.27 | |
| 97802 | 0% | 43 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCLYBURN, NEKITA (BILLING ADMINISTRATION)